Hacène Zerazhi
A5079928258- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Cancer Genomics and Diagnostics
- Cutaneous lymphoproliferative disorders research
- T-cell and Retrovirus Studies
- Cancer Mechanisms and Therapy
- Ovarian cancer diagnosis and treatment
- HIV/AIDS drug development and treatment
- Lung Cancer Research Studies
- Frailty in Older Adults
- Apelin-related biomedical research
- Hematopoietic Stem Cell Transplantation
- Hemoglobinopathies and Related Disorders
- Multiple and Secondary Primary Cancers
- Cancer Treatment and Pharmacology
- Kruppel-like factors research
Henri Gastaut Hospital
2004-2023
Laboratoire Informatique d'Avignon
2013-2022
Mantle-cell lymphoma is generally incurable. Despite high rates of complete response after initial immunochemotherapy followed by autologous stem-cell transplantation, patients have relapses. We investigated whether rituximab maintenance therapy at a dose 375 mg per square meter body-surface area administered every 2 months for 3 years transplantation would prolong the duration response.
Rituximab/chemotherapy is a cornerstone of treatment for Waldenström's macroglobulinemia (WM). In addition, bortezomib has shown significant activity in WM. This study evaluated the efficacy and safety dexamethasone, rituximab, cyclophosphamide (DRC) as first-line WM.In this European study, treatment-naïve patients were randomly assigned to DRC or bortezomib-DRC B-DRC six cycles. The primary end point was progression-free survival. Secondary points included response rates, overall survival,...
Summary The peripheral blood lymphocyte‐to‐monocyte ratio (LMR) has been shown to predict outcomes in follicular lymphoma (FL). Among 1018 patients from the RELEVANCE trial (for previously untreated, high tumour burden FL), median LMR was 2.5 (range, 0.3–93.5) and an cut‐off of 2 mostly associated with survival end‐points. Patients ≤2 ( n = 372; 37%) were older had higher risk disease. An a shorter progression‐free (PFS) (hazard [HR] 1.39, p 0.002) overall (OS) (HR 1.44, 0.049). association...
We present results of a prospective, multicenter, phase II study evaluating rituximab, bendamustine, bortezomib and dexamethasone as first-line treatment for patients with mantle cell lymphoma aged 65 years or older. A total 74 were enrolled (median age, 73 years). Patients received maximum six cycles at 28-day intervals. The primary objective was to achieve an 18-month progression-free survival rate 65% higher. Secondary objectives evaluate toxicity the prognostic impact index, Ki67...
Acute myeloid leukemia (AML) in elderly patients has a poor prognosis. In an attempt to improve outcome for these patients, the prospective open-label phase III LAM-SA 2007 (Adding Lomustine Chemotherapy Older Patients With Myelogenous Leukemia (AML), and Allogeneic Transplantation From 60 65 Years Old) trial randomly assigned standard induction regimen with lomustine added or consolidation cytarabine idarubicin.Adults age years older previously untreated AML who were fit receive intensive...
Although interferon (IFN) has been used in elderly patients with acute lymphoblastic leukemia (ALL), the benefits from IFN therapy have not properly assessed, especially as it was given combined other cytotoxic drugs, which obscured role of if any. In 1997, we started a study aimed at improving our previous results ALL and assessing therapeutic this disease. Fifty-eight ALL, aged 55-81 years (median: 64.9 years), were randomly allocated to treatment vindesine or vincristine during induction....
We evaluated the impact of genetic changes within p6 Gag gene on virological response (VR, mean decrease in plasma viral load at week 12) to unboosted amprenavir (APV). Gag-protease fragments, including gag p2, p7, p1, regions and whole protease (PR) were sequenced from baseline specimens 84 highly pre-treated but APV-naive patients included NARVAL (ANRS 088) trial. The correlation between polymorphism, PR mutations, characteristics VR APV was analysed univariate analysis. Insertions...
Abstract BACKGROUND Optimal treatment of human immunodeficiency virus (HIV)‐associated non‐Hodgkin lymphoma (NHL) has yet to be defined, because chemotherapy could exacerbate immunodeficiency, with subsequent adverse effects for patients. METHODS The authors investigated the feasibility an intensive regimen HIV‐associated NHL. Thirty‐eight patients were treated a first course cyclophosphamide (Cy), vincristine, and prednisone; followed by 3 courses high‐dose Cy (2000 mg/m 2 ), doxorubicin...
Ruxolitinib was recently approved for the treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea based on data from RESPONSE studies. This phase 3b, Expanded Treatment Protocol study (NCT02292446) ruxolitinib hydroxyurea-resistant/intolerant (N = 161: median exposure 25.1 weeks) further evaluated safety ruxolitinib. Adverse events (AEs) led dose adjustment/interruption in 37.9% and drug discontinuation 8.7% patients. The most common hematologic AEs included...
Introduction: The peripheral blood LMR has been postulated as an accessible piece of information about the composition tumor microenvironment. In a single-center, retrospective, unselected cohort FL, low was shown to be associated with older age and higher burden predict for shorter progression-free overall survival (PFS, OS) risk histological transformation second primary malignancies (Mozas, Leuk & Lymph, 2020). We explored impact in patients included phase III RELEVANCE trial...
Between 2011 and 2012, a phase II trial evaluated the use of RiBVD (rituximab, bendamustine, velcade dexamethasone) combination as first-line treatment for mantle cell lymphoma (MCL) patients over age 65. We have now re-examined classic prognostic factors, adding an assessment TP53 mutation status. Patients (N=74; median 73 years) were treated with combination. Median progression-free survival (mPFS) was 79 months overall (mOS) 111 months. status available 54/74 (73%) patients. mutations...
The impact of conventional treatment for acute myeloid leukemia (AML) on the nutritional, cognitive, and functional status elderly patients is seldom studied. This assessment was performed in context LAMSA 2007 trial.The trial enrolled 424 with de novo AML. Among them, 316 benefited from geriatric (GA) including were scored according to Eastern Cooperative Oncology Group (ECOG) sorror prediction toxicity, morbidity, mortality. Patients investigated at diagnosis three times during...
Mantle cell lymphoma (MCL) accounts for approximately 6% of non-Hodgkin (NHL) in adults. MCL commonly responds to initial therapy but inevitably patients relapse and response duration decreases from one salvage the next. Indeed, there is an urgent need control and/or eradicate residual cells that are responsible early late relapses. Maintenance with Rituximab (RM) after R-CHOP has been shown prolong OS elderly treated (Kluin-Nelemans et al. NEJM). Induction high-dose cytarabine followed by...